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Background. The transforming growth factor (TGF)-b and vascular endothelial growth factor (VEGF) pathways have a major role in
the pathogenesis of glioblastoma, notably immunosuppression, migration, and angiogenesis, but their interactions have re-
mained poorly understood.
Methods.We characterized TGF-b pathway activity in 9 long-term glioma cell lines (LTCs) and 4 glioma-initiating cell lines (GICs) in
relation to constitutive and exogenous TGF-b-induced VEGF release. Results were validated using The Cancer Genome Atlas tran-
scriptomics data.
Results. Glioma cells exhibit heterogeneous patterns of constitutive TGF-b pathway activation reflected by phosphorylation not
only of SMAD2 and SMAD3 but also of SMAD1/5/8. Constitutive TGF-b pathway activity depends on the type I TGF-b receptor, ALK-
5, and accounts for up to 69% of constitutive VEGF release, which is positively regulated by SMAD2/3 and negatively regulated by
SMAD1/5/8 signaling in a cell line-specificmanner. Exogenous TGF-b induces VEGF release inmost cell lines in a SMAD- and ALK-5–
dependent manner. There is no correlation between the fold induction of VEGF secretion induced by TGF-b compared with hyp-
oxia. The role of SMAD5 signaling is highly context and cell-line dependent with a VEGF inhibitory effect at low TGF-b and pSMAD2
levels and a stimulatory effect when TGF-b is abundant.
Conclusions. TGF-b regulates VEGF release by glioma cells in an ALK-5–dependent manner involving SMAD2, SMAD3, and SMAD1/
5/8 signaling. This crosstalk between the TGF-b and VEGF pathways may open up new avenues of biomarker-driven exploratory
clinical trials focusing on the microenvironment in glioblastoma.
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Transforming growth factor (TGF)-b, a cytokine with pleiotropic
functions, plays a pivotal role in cancer biology and represents
one of the key pathogenic factors in glioblastoma. Ligand bind-
ing leads to the phosphorylation of SMAD family proteins that
are involved in the regulation of gene transcription. Activation
of the TGF-b/SMAD pathway correlates with poor prognosis in
glioma patients.1 Various anti–TGF-b strategies have been ex-
plored in rodent glioma models2–5 and clinical trials.6,7
TGF-b signaling is mediated via a heterodimeric receptor
complex comprising type I and type II receptors.8 Canonical
TGF-b signaling involves ligand binding to TGF-b receptor II
(TGF-bRII), which associates with the type I receptor activin
receptor-like kinase-5 (ALK-5) resulting in the phosphorylation
of SMAD2 and SMAD3.9 Pharmacological ALK-5 inhibition is
an effective treatment strategy in rodent glioma models.4,5,10
The involvement of another type I receptor in TGF-b signaling,
the activin receptor-like kinase 1 (ALK-1), leading to the phos-
phorylation of SMAD1/5/8, has been characterized in endothe-
lial cells.11 This alternative pathway may counteract the ALK-5/
pSMAD2 pathway and thereby balance TGF-b signaling.
A role for TGF-b in modulating vascular endothelial growth
factor (VEGF) release has been proposed in several cell types.
Both negative and positive regulation of VEGF by TGF-b has
been described in endothelial cells.12,13 In glioma cells, the ef-
fect of TGF-b on the regulation of VEGF release also remains un-
certain. For selected glioma cell lines, a time-dependent
increase of VEGF release induced by exogenous TGF-b has
been reported.14 Silencing of TGF-b1/2 or exposure to the
ALK-5 inhibitor, SD-208, led to reduced VEGF levels in the super-
natant of LN-308 and LNT-229 glioma cells, indicating a role for
TGF-b1/2 in the regulation of constitutive VEGF release in vitro.
15
However, pharmacological inhibition of ALK-5 by SB431542
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inhibited the TGF-b–evoked VEGF release but had only minor
effects on constitutive VEGF release in D270MG or D423MG
cells.16 These observations raise the possibility that VEGF is
not only regulated via pSMAD2/3 signaling but also involves
other pathways in glioma cells.
Materials and Methods
Cell Culture
Nine long-term malignant glioma cell lines (LTCs),17 4
glioma-initiating cell lines (GICs),18,19 and hCMEC/D320 (Supple-
mentary material) were incubated under normoxia or in a hyp-
oxia incubator (1% O2, 5% CO2, 378C).
Reagents
Recombinant TGF-b2 (R&D Systems) was used for all stimula-
tion studies. SD-208 (Scios Inc.) inhibits ALK-5 at 0.048 mM in
cell-free systems.4
Immunoblot Analyses
Whole cell lysates were subjected to SDS-PAGE under reducing
conditions loading equal amounts of proteins (Supplementary
material). Short interference RNA (siRNA)-mediated knockdown
was applied to identify the specific band. For quantitative cor-
relation analyses of baseline expression of total and phosphor-
ylated SMAD proteins, band intensity was analyzed via
densitometry using ImageJ software (open source). To com-
pare the relative induction of phosphorylation after stimulation,
we scored the responses into no (,20%), low (20%–50%), me-
dium (.50%) or high induction of phosphorylation (.100% or
no baseline phosphorylation).
Real-time Polymerase Chain Reaction
Gene expression was determined via real-time polymerase
chain reaction (RT-PCR; see Supplementary material for proce-
dure and primer sequences) using glycerinaldehyde-3-
phosphate dehydrogenase (GAPDH) as a housekeeping gene
with the DCTT-method for relative quantification.
RNA Interference
To silence gene expression, cells were transiently transfected
using Metafectene Pro (Biontex) for LTCs and electroporation
for GICs (Neon Transfection System, Invitrogen) and siRNA
pools (80–120 nM final concentration), containing 4 selected
siRNA duplexes, each with a modification pattern addressing
off-target effects caused by both strands (ON-TARGETplus,
SMARTpool, ON-TARGETplus Non-targeting siRNA Pool as a neg-
ative control; Dharmacon).
Flow Cytometry
Signal intensity of flow cytometry analysis (Supplementary ma-
terial) was calculated as the ratio of mean fluorescence of spe-
cific versus isotype control antibody (specific fluorescence
index).
Enzyme-linked Immunosorbent Assay
Supernatants (preparation as outlined in the Supplementary
material) were analyzed by ELISA for VEGF levels (eBioscience)
and TGF-b1/2 (R&D Systems).
Luciferase Reporter Assay
The pGL3 SBE-4-Luc plasmid (B. Vogelstein) containing 4 copies
of the SMAD-binding element (SBE) GTCTAGAC21 was used for
reporter gene assays (Supplementary material).
Results
TGF-b Pathway Activity in Human Glioma Cells
We first analyzed the expression levels of TGF-b receptors, their
ligands, constitutive levels of total SMAD2-5, phosphorylated
SMAD2, SMAD3 and SMAD1/5/8, and the TGF-b target gene plas-
minogen activator inhibitor (PAI)-1. Correlation analyses of these
parameters were performed either for all cell lines pooled or sep-
arately for LTCs (Table 1). A separate analysis for the GICs was
omitted because of small sample size. We validated our results
using Affymetrix gene expression data from the The Cancer Ge-
nome Atlas (TCGA) (Supplementary material, Table S1).
TGF-bRII, ALK-5, and ALK-1 messenger RNA (mRNA) were
differentially expressed with a trend towards lower mRNA ex-
pression for all receptors in GICs. ALK-1 mRNA levels were
lower than ALK-5 levels and more than 100 times lower in gli-
oma than in endothelial cells (Fig. 1A–C, left). The highest
TGF-bRII protein levels were found for T98G cells, while 2 of 4
GICs (T-269, S-24) had TGF-bRII levels at the detection limit.
The specific fluorescence index varied strongly for ALK-5 from
84 in LN-18 cells to 1.7 in LN-308 cells. ALK-1 protein was not
detected at the cell surface in glioma cells using hCMEC as a
positive control (Fig. 1A–C, right). Overall, mRNA levels were
not predictive of protein levels. TGF-b1 and TGF-b2 were hetero-
geneously expressed on mRNA and protein level (Fig. 1D and E).
TGF-b1 mRNA correlated with secreted TGF-b1 but not with
TGF-b2 mRNA or protein. TGF-b2 mRNA correlated with
TGF-bRII mRNA in our dataset as well as TCGA database
(Table 1; Supplementary material, Table S1).
pSMAD2 levels were highest in LN-428, LN-319, A172 and
LN-308, less in LN-18, D247 and T98G cells, below detection
limit in the other cell lines, and correlated with pSMAD3 levels.
pSMAD1/5/8 was low in 2 of 4 GICs (Fig. 1F). TGF-bRII and ALK-5
mRNA correlated with pSMAD2, and TGF-bRII surface expres-
sion with pSMAD1/5/8 levels. Phosphorylation of SMAD proteins
as the proximate readout of TGF-b activity correlated with li-
gand expression as follows: pSMAD2 with TGF-b1 and TGF-b2
mRNA; pSMAD3 and pSMAD1/5/8 with TGF-b2 protein and in-
versely SMAD5 protein with the sum of TGF-b1 and TGF-b2 pro-
tein. PAI-1 mRNA levels did not correlate with TGF-b receptors,
ligands (mRNA or protein), or downstream phosphorylation of
SMAD (Fig. 1G, Table 1).
Endogenous TGF-b Promotes VEGF Expression and
Release in a Cell Line-specific Manner
VEGF expression on mRNA or protein level was similar in LTCs
and GICs (Fig. 2A and B). TGF-b1 mRNA correlated with VEGF
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Table 1. Correlation analyses for components of the TGF-b signaling pathway and vascular endothelial growth factor for all cell lines pooled (upper right) and long-term glioma cell lines separately (lower left)
TGF-b1 mRNA TGF-b2 mRNA TGF-b1 protein TGF-b2 protein TGF-b1 + 2 protein SMAD2protein pSMAD2 SMAD3 protein pSMAD3 SMAD5 protein
TGF-b1 mRNA n/a r¼ 0.43; P¼ .14 r¼ 0.62; *P¼ .03 r¼ 0.12; P¼ .69 n/a r¼ 0.13; P¼ .68 r¼ 0.58; *P¼ .04 r¼ 0.10; P¼ .73 r¼ 0.43; P¼ .15 r¼20.03; P¼ .91
TGF-b2 mRNA r¼20.35; P¼ .36 n/a r¼ 0.04; P¼ .90 r¼ 0.15; P¼ .62 n/a r¼20.02; P¼ .94 r¼ 0.73; *P¼ .004 r¼20.13; P¼ .67 r¼ 0.37; P¼ .21 r¼ 0.31; P¼ .31
TGF-b1 protein r¼ 0.58; P¼ .11 r¼20.23; P¼ .55 n/a r¼ 0.06; P¼ .84 n/a r¼20.30; P¼ .32 r¼ 0.25; P¼ .40 r¼ 0.13; P¼ .67 r¼ 0.34; P¼ .24 r¼20.45; P¼ .13
TGF-b2 protein r¼ 0.23; P¼ .55 r¼20.17; P¼ .68 r¼ 0.45; P¼ .23 n/a n/a r¼ 0.44; P¼ .13 r¼ 0.36; P¼ .23 r¼20,16; P¼ .61 r¼ 0.59; *P¼ .03 r¼ 0.06; P¼ 0.86
TGF-b1+2 protein n/a n/a n/a n/a n/a r¼20.16; P¼ .60 r¼ 0.09; P¼ .76 r¼20.13; P¼ .68 r¼ 0.52; P¼ .07 *r¼20.59; P¼ .03
SMAD2 protein r¼ 0.27; P¼ .49 r¼20.32; P¼ .41 r¼20.17; P¼ .68 r¼ 0.20; P¼ .61 r¼20.07; P¼ .88 n/a r¼ 0.29; P¼ .36 r¼20.03; P¼ .93 r¼ 0.45; P¼ .13 r¼ 0.30; P¼ .32
pSMAD2 r¼20.07; P¼ .88 r¼ 0.30; P¼ .44 r¼ 0.10; P¼ .81 r¼ 0.60; P¼ .10 r¼ 0.07; P¼ .88 r¼ 0.30; P¼ 0.44 n/a r¼20.27; P¼ .37 r¼ 0.62; *P¼ .02 r¼ 0.36; P¼ .23
SMAD3 protein r¼ 0.30; P¼ .44 r¼ 0.07; P¼ .88 r¼ 0.23; P¼ .55 r¼20.03; P¼ .95 r¼ 0.23; P¼ .55 r¼ 0.03; P¼ .95 r¼20.47; P¼ .21 n/a r¼20.55; P¼ .05 r¼20.09; P¼ .76
pSMAD3 r¼ 0.35; P¼ .36 r¼20.28; P¼ .46 r¼ 0.50; P¼ .18 r¼ 0.40; P¼ .29 r¼ 0.47; P¼ .21 r¼ 0.50; P¼ .18 r¼ 0.55; P¼ .13 r¼20.38; P¼ .31 n/a r¼ 0.03; P¼ .91
SMAD5 protein r¼20.77; *P¼ .02 r¼ 0.12; P¼ .78 r¼20.82; *P¼ .01 r¼20.43; P¼ .25 r¼20.70; *P¼ .04 r¼ 0.08; P¼ 0.84 r¼20.03; P¼ .95 r¼20.53; P¼ .15 r¼20.15; P¼ .71 n/a
pSMAD1/5/8 r¼ 0.17; P¼ .68 r¼20.43; P¼ .25 r¼ 0.08; P¼ .84 r¼ 0.33; P¼ .39 r¼ 0.33; P¼ .39 r¼ 0.53; P¼ .15 r¼20.13; P¼ .74 r¼ 0.63; P¼ .08 r¼20.07; P¼ .88 r¼20.30; P¼ .44
SMAD4 protein r¼20.08; P¼ .84 r¼ 0.77; *P¼ .02 r¼20.22; P¼ .58 r¼ 0.23; P¼ .55 r¼20.37; P¼ .34 r¼ 0.05; P¼ .91 r¼ 0.58; P¼ .11 r¼ 0.02; P¼ .98 r¼20.05; P¼ .91 r¼ 0; P¼ 1
TGF-bRII mRNA r¼20.03; P¼ .95 r¼ 0.50; P¼ .18 r¼20.20; P¼ .61 r¼ 0.22; P¼ .58 r¼20.28; P¼ .46 r¼20.38; P¼ .31 r¼ 0.27; P¼ .49 r¼ 0.03; P¼ .95 r¼20.50; P¼ .18 r¼20.17; P¼ .68
TGF-bRII protein r¼ 0.22; P¼ .58 r¼20.35; P¼ .36 r¼20.43; P¼ .25 r¼ 0.12; P¼ .78 r¼20.25; P¼ .52 r¼ 0.37; P¼ 0.34 r¼20.32; P¼ .41 r¼ 0.32; P¼ .41 r¼20.43; P¼ .25 r¼ 0.02; P¼ .98
ALK-5 mRNA r¼20.42; P¼ .27 r¼ 0.58; P¼ .11 r¼20.32; P¼ .41 r¼20.33; P¼ .39 r¼20.50; P¼ .18 r¼20.43; P¼ .25 r¼ 0.10; P¼ .81 r¼20.50; P¼ .18 r¼20.17; P¼ .68 r¼ 0.43; P¼ .25
ALK-5 protein r¼ 0.23; P¼ .55 r¼ 0.07; P¼ .88 r¼20.15; P¼ .71 r¼ 0.03; P¼ .95 r¼20.17; P¼ .68 r¼20.13; P¼ .74 r¼20.13; P¼ .74 r¼ 0.30; P¼ .44 r¼20.42; P¼ .27 r¼20.20; P¼ .61
ALK-1 mRNA r¼20.17; P¼ .68 r¼ 0.42; P¼ .27 r¼20.15; P¼ .71 r¼ 0.08; P¼ .84 r¼20.12; P¼ .78 r¼20.13; P¼ .74 r¼20.08; P¼ .84 r¼ 0.55; P¼ .13 r¼20.42; P¼ .27 r¼20.05; P¼ .91
VEGF mRNA r¼ 0.47; P¼ .21 r¼ 0.15; P¼ .71 r¼ 0.36; P¼ .33 r¼ 0.29; P¼ .44 r¼ 0.16; P¼ .68 r¼20.08; P¼ .84 r¼ 0.36; P¼ .34 r¼20.29; P¼ .44 r¼ 0.47; P¼ .21 r¼20.26; P¼ .49
VEGF protein r¼ 0; P¼ 1 r¼ 0.37; P¼ .34 r¼ 0.47; P¼ .21 r¼20.12; P¼ .78 r¼ 0.32; P¼ .41 r¼20.78; *P¼ .02 r¼20.37; P¼ .34 r¼ 0.40; P¼ .29 r¼20.35; P¼ .36 r¼20.42; P¼ .27
PAI-1 mRNA r¼ 0.18; P¼ .64 r¼ 0.62; P¼ .09 r¼ 0.13; P¼ .74 r¼ 0.07; P¼ .88 r¼20.03; P¼ .95 r¼20.07; P¼ .88 r¼20.03; P¼ .95 r¼ 0.67; P¼ .06 r¼20.30; P¼ .44 r¼20.43; P¼ .25
pSMAD 1/5/8 SMAD4 protein TGF-bRII mRNA TGF-bRII protein ALK-5 mRNA ALK-5 protein ALK-1 mRNA VEGF mRNA VEGF protein PAI-1 mRNA
TGF-b1 mRNA r¼ 0.20; P¼ .51 r¼ 0.07; P¼ .83 r¼ 0.41; P¼ .17 r¼ 0.35; P¼ .24 r¼ 0.31; P¼ .31 r¼ 0.41; P¼ .17 r¼ 0.33; P¼ .27 r¼ 0.55; *P¼ .05 r¼20.01; P¼ .99 r¼ 0.15; P¼ .62
TGF-b2 mRNA r¼ 0.20; P¼ .50 r¼ 0.20; P¼ .50 r¼ 0.73; *P¼ .005 r¼ 0.17; P¼ .58 r¼ 0.80; *P¼ .001 r¼ 0.32; P¼ .28 r¼ 0.52; P¼ .07 r¼ 0.14; P¼ .65 r¼20.03; P¼ .91 r¼ 0.39; P¼ .19
TGF-b1 protein r¼ 0; P¼ . 1 r¼20.04; P¼ .90 r¼20.04; P¼ .90 r¼20.04; P¼ .89 r¼20.06; P¼ .84 r¼20.06; P¼ .86 r¼ 0.09; P¼ .76 r¼ 0.60; *P¼ .03 r¼ 0.52; P¼ .07 r¼ 0.13; P¼ .68
TGF-b2 protein r¼ 0.62; *P¼ .02 r¼ 0; P¼ 1 r¼ 0.44; P¼ .20 r¼ 0.38; P¼ .13 r¼ 0.02; P¼ .95 r¼ 0.02; P¼ .94 r¼20.02; P¼ .94 r¼20.24; P¼ .43 r¼20.43; P¼ .14 r¼ 0.06; P¼ .85
TGF-b1+2 protein r¼ 0.35; P¼ .24 r¼20.20; P¼ .51 r¼ 0.07; P¼ .82 r¼ 0.27; P¼ .37 r¼20.17; P¼ .58 r¼20.09; P¼ .78 r¼20.05; P¼ .87 r¼ 0.28; P¼ .35 r¼ 0.36; P¼ 0.23 r¼ 0.25; P¼ .42
SMAD2 protein r¼ 0.55; P¼ .05 r¼20.08; P¼ .80 r¼20.03; P¼ .93 r¼ 0.24; P¼ .44 r¼20.03; P¼ .91 r¼20.07; P¼ .82 r¼20.09; P¼ .76 r¼20.37; P¼ .21 r¼20.81; *P¼ .0007 r¼20.10; P¼ .75
pSMAD2 r¼ 0.18; P¼ .55 r¼ 0.28; P¼ .36 r¼ 0.60; *P¼ .03 r¼ 0.10; P¼ .74 r¼ 0.60; *P¼ .03 r¼ 0.19; P¼ .54 r¼ 0.31; P¼ .30 r¼ 0.33; P¼ .27 r¼20.30; P¼ .31 r¼20.03; P¼ .93
SMAD3 protein r¼20.04; P¼ .89 r¼ 0.19; P¼ .54 r¼20.29; P¼ .34 r¼20.21; P¼ .49 r¼20.52; P¼ .07 r¼ 0.14; P¼ .64 r¼ 0.39; P¼ .19 r¼ 0.02; P¼ .94 r¼ 0.25; P¼ .42 r¼ 0.13; P¼ .68
pSMAD3 r¼ 0.50; P¼ .08 r¼20.19; P¼ .54 r¼ 0.35; P¼ .24 r¼ 0.26; P¼ .39 r¼ 0.43; P¼ .14 r¼20.06; P¼ .86 r¼20.09; P¼ .76 r¼ 0.08; P¼ .79 r¼20.36; P¼ .23 r¼ 0.09; P¼ .76
SMAD5 protein r¼ 0; P¼ 1 r¼ 0.31; P¼ .31 r¼ 0.19; P¼ .54 r¼20.02; P¼ .96 r¼ 0.43; P¼ .14 r¼20.13; P¼ .67 r¼ 0.27; P¼ .36 r¼20.12; P¼ .69 r¼20.64; *P¼ .02 r¼20.57; *P¼ .04
pSMAD1/5/8 n/a r¼20.23; P¼ .45 r¼ 0.38; P¼ .20 r¼ 0.71; *P¼ .007 r¼ 0.03; P¼ .91 r¼ 0.06; P¼ .91 r¼ 0.23; P¼ .46 r¼20.50; P¼ .08 r¼20.40; P¼ .17 r¼ 0.33; P¼ .27
SMAD4 protein r¼20.23; P¼ .55 n/a r¼ 0.25; P¼ .40 r¼20.02; P¼ .96 r¼20.10; P¼ .75 r¼22 0.04; P¼ .89 r¼ 0.53; P¼ .06 r¼ 0.48; P¼ .10 r¼20.11; P¼ .72 r¼20.13; P¼ .68
TGF-bRII mRNA r¼20.22; P¼ .58 r¼ 0.70; *P¼ .04 n/a r¼ 0.56; P¼ .05 r¼ 0.50; P¼ .08 r¼ 0.58; *P¼ .04 r¼ 0.45; P¼ .12 r¼ 0.10; P¼ .75 r¼20.23; P¼ .46 r¼ 0.23; P¼ .46
TGF-bRII protein r¼ 0.55; P¼ .13 r¼20.03; P¼ .95 r¼ 0.23; P¼ .55 n/a r¼ 0.09; P¼ .76 r¼ 0.35; P¼ .25 r¼ 0.37; P¼ .22 r¼20.09; P¼ .75 r¼20.27; P¼ .36 r¼ 0.29; P¼ .33
ALK-5 mRNA r¼20.73; *P¼ .03 r¼ 0.15; P¼ .71 r¼ 0.10; P¼ .81 r¼20.38; P¼ .31 n/a r¼ 0.05; P¼ .87 r¼ 0.06; P¼ .84 r¼ 0.03; P¼ .92 r¼20.10; P¼ .75 r¼ 0.15; P¼ .62
ALK-5 protein r¼ 0.03; P¼ .95 r¼ 0.45; P¼ .23 r¼ 0.72; *P¼ .04 r¼ 0.47; P¼ .21 r¼20.43; P¼ .25 n/a r¼ 0.40; P¼ .17 r¼ 0.23; P¼ .45 r¼20.02; P¼ .94 r¼ 0.19; P¼ .53
ALK-1 mRNA r¼ 0.18; P¼ .64 r¼ 0.60; P¼ .10 r¼ 0.52; P¼ .16 r¼ 0.22; P¼ .58 r¼20.33; P¼ .39 r¼ 0.70; *P¼ .04 n/a r¼ 0.32; P¼ .28 r¼ 0.03; P¼ .94 r¼ 0.20; P¼ .52
VEGF mRNA r¼20.56; P¼ .12 r¼ 0.46; P¼ .21 r¼ 0.30; P¼ .44 r¼20.24; P¼ .52 r¼ 0.04; P¼ .91 r¼ 0.35; P¼ .36 r¼ 0.13; P¼ .74 n/a r¼ 0.33; P¼ .27 r¼20.09; P¼ .77
VEGF protein r¼20.22; P¼ .58 r¼20.10; P¼ .81 r¼ 0.10; P¼ .81 r¼20.40; P¼ .29 r¼ 0.32; P¼ .41 r¼20.12; P¼ .78 r¼ 0.13; P¼ .74 r¼20.03; P¼ .95 n/a r¼ 0.46; P¼ .11
PAI-1 mRNA r¼ 0.20; P¼ .61 r¼ 0.42; P¼ .27 r¼ 0.25; P¼ .52 r¼ 0.07; P¼ .88 r¼ 0.17; P¼ .68 r¼ 0; P¼ 1 r¼ 0.35; P¼ .36 r¼20.08; P¼ .84 r¼ 0.53; P¼ .15 n/a



















Fig. 1. TGF-b receptor expression and TGF-b pathway activity in human glioma cells. (A–C) Expression levels of TGF-b-RII (A), ALK-5 (B) and ALK-1
(C) on mRNA level assessed by RT-PCR (left) and protein level (specific fluorescence index) assessed by flow cytometry (middle) (A and B).
Representative flow cytometric profiles are shown on the right. Data are expressed as mean and SEM of 2–4 independent experiments. (D)
Expression of TGF-b1 (squares) and TGF-b2 (circles) mRNA assessed by RT-PCR. (E) Long-term glioma cell lines (LTCs) were serum starved for
24 hours and then exposed to serum-free medium for 24 hours. Glioma-initiating cell lines (GICs) were seeded, changed to fresh
medium24 hours later, and supernatants were harvested 24 hours thereafter. TGF-b1 (open bars) or TGF-b2 (striped bars) released into the
supernatant were analyzed by ELISA (mean and SEM, n¼ 2, in duplicates; n.d., below detection limit). (F) Whole cell lysates of LTCs (serum
starved for24 h) or GICs were subjected to immunoblotting. Representative loading controls for GAPDH or b-actin were included. (G) PAI-1
mRNA expression assessed by RT-PCR.
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Fig. 2. Control of VEGF release by constitutive TGF-b pathway activity. (A) VEGF mRNA analyzed by RT-PCR and VEGF release into the supernatant
(B) prepared as in Fig. 1D and analyzed by ELISA (mean and SEM, n¼ 5 in duplicates or triplicates) in long-term glioma cell lines (LTCs) and
glioma-initiating cell lines (GICs). (C) Representative immunoblots (SMAD2, pSMAD2, SMAD3, pSMAD3, SMAD5, pSMAD1/5/8, GAPDH) of LN-308
cells after transfection with siRNA targeting TGF-bRII (72 h) or ALK-5 (48 h) or after pharmacologicial inhibition of ALK-5 by SD-208 (1 mM,
24 h, or respective controls (nontargeting siRNA or DMSO). (D) Representative immunoblots of LN-308 cells with siRNA targeting SMAD2 (48 h),
SMAD3 (48 h), SMAD2, and SMAD3 (48 h), or SMAD5 (72 h) or nontargeting control. (E) Supernatants of LN-308 cells harvested 72 hours after
transfection with siRNA targeting TGF-bRII were assessed for VEGF levels by ELISA. (F) Supernatants of U87MG, LN-308, and ZH-161 cells were
analyzed for VEGF by ELISA after exposure to ALK-5 siRNA (left, 48 h post transfection for LN-308 and ZH-161, 72 h for U87MG) or SD-208
(right, 24 h, 1 mM). (G and H) Supernatants harvested after transfection with siRNA targeting SMAD2 (24 h for U87MG and ZH-161, 48 h for
LN-308), SMAD3 (36 h for U87MG, 48 h for LN-308, 24 h for ZH-161), SMAD2/3 (36 h for U87MG, 48 h for LN-308, 24 h for ZH-161) (G), or
SMAD5 (24 h for U87MG and ZH-161, 48 h for LN-308) (H). The representative experiments shown were performed in triplicate (Student t test,
*P, .05).
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mRNA, while total SMAD2 and total SMAD5 protein were in-
versely correlated with VEGF release. TGF-b1 and TGF-b2
mRNA correlated with VEGFmRNA and also correlated inversely
with SMAD2 mRNA in the TCGA database. However, neither
TGF-b receptor mRNA nor protein in our cell line panel nor
gene expression data of the TCGA nor pSMAD2/pSMAD3 nor
pSMAD1/5/8 levels correlated with VEGF mRNA. PAI-1 mRNA
correlated with VEGF mRNA in the TCGA but not in our dataset
(Table 1; Supplementary material, Table S1).
We chose LN-308 cells to study the regulation of constitutive
VEGF release because of their high endogenous TGF-b expres-
sion and high constitutive SMAD2 and SMAD3 phosphorylation.
We added selected analyses for U87MG and ZH-161 cells. In
LN-308, TGF-bRII silencing with an efficacy of 88% reduction
assessed by RT-PCR (data not shown) reduced pSMAD2 and
pSMAD3 levels and confirmed the involvement of TGF-b and
TGF-bRII in their constitutive regulation. Interestingly,
pSMAD1/5/8 levels were also reduced upon silencing of
TGF-bRII. Pharmacological inhibition of the kinase activity of
ALK-5 by the small molecule inhibitor SD-208 or silencing of
ALK-5 also led to reduced pSMAD2 and pSMAD3 levels but did
not affect constitutive pSMAD1/5/8 levels (Fig. 2C). To investi-
gate the contribution of the different SMAD signaling pathways
to constitutive VEGF release, we established gene silencing of
SMAD2, SMAD3, SMAD2/3 in combination, or SMAD5, which
led to specific reductions of the corresponding target proteins.
As expected, pSMAD2, pSMAD3, and pSMAD1/5/8 were also re-
duced upon silencing of the respective SMAD proteins. In addi-
tion, silencing of SMAD proteins did not affect only their own
phosphorylation; instead, we observed reduced pSMAD3 upon
silencing of SMAD2 in contrast with increased pSMAD2 upon si-
lencing of SMAD3. pSMAD3 was increased upon silencing of
SMAD5, while pSMAD2 was unaffected (Fig. 2D).
Silencing of TGF-bRII reduced VEGF release in LN-308 cells
(Fig. 2E). Inhibition of ALK-5 by RNA interference or SD-208
also reduced VEGF release in U87MG and LN-308 cells, although
the reduction was not significant in ZH-161 (Fig. 2F). SMAD si-
lencing had differential effects on VEGF release: SMAD2 or
SMAD3 gene silencing reduced constitutive VEGF levels in
U87MG and LN-308 but not in ZH-161 (Fig. 2G). Even cosilenc-
ing of SMAD2 and SMAD3 failed to affect VEGF release in
ZH-161, but further reduced VEGF levels in LN-308 compared
to the effect of silencing SMAD2 or SMAD3 alone. In contrast,
silencing of SMAD5 increased the levels of constitutive VEGF re-
lease in U87MG cells but had no effects in LN-308 or ZH-161
(Fig. 2H).
Exogenous TGF-b Promotes VEGF Release in Human
Malignant Glioma Cells
We next assessed glioma cell response to exogenous TGF-b. All
cell lines showed increased pSMAD2 and (except for S-24) in-
creased pSMAD3, albeit to a different extent. The relative induc-
tion of pSMAD2 correlated inversely with the endogenous
pSMAD2 (r¼20.66; P¼ .01). pSMAD1/5/8 was increased in
LN-319, A172, and U87MG LTCs as well as T-325, ZH-161,
and S-24 GICs (Fig. 3A). We next monitored the increase of
TGF-b–dependent transcriptional activity using a SBE reporter
plasmid.21 TGF-b induced SBE reporter activity in all cell lines
except in LN-428, A172, T-269, and S-24 cells. The highest
response was observed in U87MG (26-fold) (Fig. 3B). Sufficient
TGF-bRII surface expression was necessary for the induction of
SBE reporter activity given the poor response in T-269 and S-24
cells, which exhibited TGF-bRII levels at the detection limit
(Fig. 1A). In addition, high responsiveness correlated with
pSMAD3 induction by TGF-b (r¼ 0.62; P¼ .02). Surprisingly,
the reporter-nonresponsive cell lines LN-428 and A172 ex-
pressed high levels of ALK-5, in contrast with the highly respon-
sive cell line U87MG (Fig. 1B).
VEGF levels increased after TGF-b treatment in all cell lines
except LN-428, A172, and S-24. The most pronounced increase
was seen in U87MG cells (9-fold) (Fig. 3C). The response in
U87MG was maintained but reduced in extent when those
cells were switched to GIC culture conditions. In ZH-161, the re-
sponse was further increased when switched to serum-
containing medium for 2 passages. Under GIC conditions,
basal VEGF synthesis was increased in U87MG, both on mRNA
and protein levels, and in ZH-161 on protein level (Supplemen-
tary material, Fig. S1). Cell lines not exhibiting TGF-b2–depen-
dent VEGF induction showed only minor induction of pSMAD2
and pSMAD3 by TGF-b2 (Fig. 3A). The induction of VEGF by
TGF-b correlated with the induction of pSMAD3 (r¼ 0.59; P¼
.04) and reporter responsiveness (r¼ 0.71; P¼ .006). To assess
whether cell lines not increasing VEGF release in response to
TGF-b were generally less responsive to transcriptional activa-
tion of the VEGF gene, we exposed the same cell lines to hyp-
oxia (1% O2, 24 h) as a major driver of VEGF gene
transcription.22 Hypoxia led to increased VEGF levels in almost
all cell lines including LN-428, A-172, and S-24, which did not
increase VEGF release upon stimulation with TGF-b. Conversely,
LNT-229 cells were unaffected, and D247MG even showed re-
duced VEGF release under hypoxia (Fig. 3D). Of note,
hypoxia-induced VEGF release was higher overall in GICs, rang-
ing from 1.9-fold (ZH-161) to 32-fold (T-269) than in LTCs, rang-
ing from 1.3-fold (LN-18) to 2.1-fold (U87MG). Accordingly, we
found only minor induction of HIF-1a protein by hypoxia in
LNT-229, which increased VEGF release in response to TGF-b
but not to hypoxia. Indeed, we detected higher HIF-1a protein
levels in ZH-161 than in LNT-229 cells under normoxic condi-
tions. Of note, treatment with TGF-b left HIF-1a protein unaf-
fected, and there was no correlation between the magnitude
of the VEGF response to TGF-b versus hypoxia (data not
shown). We selected U87MG and ZH-161 cells to examine the
time and concentration dependence of VEGF induction by
TGF-b. On mRNA level, the highest increase of VEGF (14-fold
for U87MG and 1.4-fold for ZH-161) was observed at 4 hours
for U87MG and at 24–48 hours for ZH-161 (Fig. 3E). The induc-
tion of VEGF release into the supernatant was highest at 9-fold
at 24 hours in U87MG cells and 2-fold at 24–48 hours in
ZH-161 cells (Fig. 3F). Furthermore, the induction of VEGF was
concentration dependent in U87MG and ZH-161 cells both on
mRNA (Fig. 3G) and protein level (Fig. 3H).
Molecular Pathways Mediating TGF-b–evoked VEGF
Release in Glioma Cells
To explore the pathwaysmediating the stimulatory effect of ex-
ogenous TGF-b on VEGF release, we combined the inhibition of
ALK-5 by SD-208 or siRNA, or siRNA-mediated gene silencing of
SMAD2, SMAD3 or SMAD5, with the addition of exogenous
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Fig. 3. Stimulation of VEGF release by exogenous TGF-b. (A) TGF-b pathway inducibility was examined by assessing the induction of pSMAD2,
pSMAD3, or pSMAD1/5/8 via immunoblot with or without stimulation with TGF-b2 (10 ng/mL) for 24 hours after 24 hour serum starvation.
Shown are immunoblots of SMAD2, pSMAD2, SMAD3, pSMAD3, SMAD5, pSMAD1/5/8, and representative loading controls for GAPDH and
b-actin. (B) Transcriptional activation by TGF-b was assessed by a SBE reporter assay. Shown are relative units of SBE reporter signal after
stimulation with TGF-b2 (10 ng/mL) for 24 hours normalized to untreated control. (C and D) The supernatants of glioma cell lines maintained
with or without 10 ng/mL TGF-b2 for 24 hours (C) or with or without hypoxia (D) after a 24 hours of serum starvation were analyzed for VEGF
by ELISA. (E and F) VEGF was assessed after 4, 24 and 48 hour exposure to 10 ng/mL TGF-b2 in U87MG or ZH-161 on mRNA level (E) or protein
level using cell culture supernatants as in A (F). (G and H) U87MG or ZH-161 cells were analyzed for VEGFafter 24 hour stimulation with TGF-b2 at 0,
0.1, 1 or 10 ng/mL on mRNA level (G) and in cell culture supernatants (H).
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TGF-b2. As expected, inhibition of ALK-5 by SD-208 or RNA inter-
ference reduced TGF-b2–evoked SMAD2 and SMAD3 phosphor-
ylation in U87MG and ZH-161 cells. Interestingly, the induction
of SMAD1/5/8 phosphorylation was also abrogated by inhibition
or silencing of ALK-5, suggesting a hitherto unrecognized
TGF-b–dependent signal transduction pathway from ALK-5 to
SMAD1/5/8 in glioma cells. Both pharmacological inhibition and
silencing of ALK-5 interfered with the TGF-b2–mediated in-
crease of VEGF (Fig. 4A, right panel). Silencing of SMAD2,
SMAD3 or SMAD5 in U87MG or ZH-161 cells led to specific re-
ductions of the target protein and reduced pSMAD2, pSMAD3,
and pSMAD1/5/8 levels, respectively (Fig. 4B). Interestingly,
TGF-b2– induced SMAD1/5/8 phosphorylation was further in-
creased in the case of SMAD2 or SMAD3 gene silencing in
U87MG but not in ZH-161, consistent with substrate competi-
tion of SMAD proteins for ALK-5 (Fig. 4B). TGF-b2–evoked tran-
scriptional activity was reduced upon silencing of either SMAD2,
SMAD3, or SMAD5 in U87MG. A similar trend was observed in
ZH-161; however, the reduction was only significant upon si-
lencing of SMAD3 alone or combined with SMAD2 (Fig. 4C). In
both cell lines, the TGF-b –evoked VEGF release was reduced
upon silencing of SMAD2 or SMAD3. Cosilencing of SMAD2 and
SMAD3 had no superior effect over single silencing in ZH-161.
Further, silencing of SMAD5 reduced TGF-b2–evoked VEGF re-
lease in U87MG, but the reduction was not significant in
ZH-161 cells (Fig. 4D).
Discussion
Targeting angiogenesis is one of themajor current strategies for
glioblastoma treatment, but enthusiasm for this approach has
declined after the failure of several antiangiogenic agents in
phase III trials.23–25 Although the anti-VEGF antibody bevaci-
zumab showed activity for recurrent glioblastoma in phase II
trials,26,27 no survival gain was achieved in 2 phase III trials
in newly diagnosed glioblastoma patients.28,29 Further, various
attempts to improve antiangiogenic therapy by combination
with cytotoxics were unsuccessful.30 Nevertheless, VEGF is
still one of the most promising targets that interferes with
the malignant phenotype of glioblastoma. While hypoxia is
considered the key driver of VEGF release in glioblastoma,
hypoxia-independent control of VEGF release has received little
attention.
TGF-b, an important molecule shaping the microenviron-
ment in glioblastoma, was characterized here as a positive reg-
ulator of the VEGF pathway.We have provided a comprehensive
analysis of the TGF-b pathway and its control of VEGF release in
LTC and GIC models. Specifically, we analyzed the role of en-
dogenous TGF-b as a model of autocrine signaling versus
that of exogenous TGF-b, mimicking paracrine signals from
the microenvironment. As a precondition for autocrine signal-
ing, TGF-bRII and ALK-5 were widely expressed, whereas
ALK-1 was not (Fig. 1), which indicates that an ALK-1/
pSMAD1/5/8 signaling axis of VEGF release characterized in en-
dothelial cells12 does not operate in glioma cells. All LTCs re-
leased TGF-b1 and TGF-b2, but TGF-b2 was not detected in 2
of 4 GICs, confirming that therapeutic approaches targeting
only one TGF-b isoform are insufficient. Most cell lines exhibited
phosphorylated SMAD2, SMAD3, or SMAD5, suggesting consti-
tutive TGF-b pathway activation, confirmed by reduced
pSMAD levels when TGF-bRII or ALK-5 expression were sup-
pressed, or when ALK-5 was inhibited pharmacologically
(Fig. 2C). In nonendothelial cells, bone morphogenetic proteins
(BMP) are considered as major drivers of SMAD1/5/8 phosphor-
ylation; however, TGF-b–dependent phosphorylation of
SMAD1/5/8 has been recently described (although not yet for
glioma cells).31,32 We found that pSMAD1/5/8 levels in cellular
lysates correlated with TGF-bRII levels at the surface and that
TGF-bRII gene silencing reduced pSMAD1/5/8 levels (Fig. 2C).
That inhibition of ALK-5 via SD-208 or ALK-5 gene silencing
left pSMAD1/5/8 unaffected suggests that a type-I receptor
other than ALK-5 mediates SMAD1/5/8 phosphorylation in re-
sponse to TGF-b. Still, we cannot rule out that these effects
are mediated via minor ALK-1 levels escaping detection on pro-
tein level.
To study the effect of endogenous TGF-b signaling on consti-
tutive VEGF release, we experimented with different compo-
nents of the TGF-b pathway. TGF-bRII gene silencing reduced
VEGF release in LN-308 cells, which confirmed a role for
TGF-b in the regulation of VEGF release in this cell line that re-
leases high levels of active TGF-b33,34 (Fig. 2E). Furthermore,
VEGF release required ALK-5 activity in LN-308 and U87MG
cells but not in ZH-161 cells (Fig. 2F). This might suggest a ro-
bust TGF-b–independent VEGF secretion in GICs, which was po-
tentially due to constitutive HIF expression at normoxic
conditions35 and was confirmed for ZH-161. SMAD2 and
SMAD3 are necessary for TGF-b–dependent regulation of
VEGF in LN-308 and U87MG cells, but again ZH-161 was unaf-
fected, even by the combined SMAD2/3 silencing that reduced
VEGF most efficiently in LN-308 cells (Fig. 2G). The role of
SMAD5 in the regulation of constitutive VEGF release is more
complex. LN-308 and ZH-161 did not show major changes
upon SMAD5 gene silencing, whereas U87MG showed increased
VEGF secretion (Fig. 2H). This can be explained by an indirect ef-
fect of BMP-2 being expressed by U87MG36 and destabilizing
HIF-1a in glioma cells.37 Thus, depletion of SMAD5, resulting
in reduced BMP signaling, might increase the stability of
HIF-1a and thereby promote VEGF release. Furthermore, a di-
rect inhibitory effect of BMP-9 on VEGF via ALK-1/pSMAD1/5/8
signaling has been described in endothelial cells.38 Thus,
TGF-b contributes to constitutive VEGF release in glioma cells
via a TGF-bRII/ALK-5/SMAD2/3 signaling pathway. The
pSMAD1/5/8 signaling axis, which is driven by both TGF-b and
BMP, might be indirectly involved in selected cell lines, possibly
as a negative feedback mechanism.
TGF-b is secreted not only by glioma cells but also by the
tumor microenvironment (eg, endothelial, immune, or micro-
glial cells). Thus, we studied the effect of exogenous TGF-b on
VEGF release. We observed a differential pattern of responsive-
ness to TGF-b as determined by changes in SMAD phosphoryla-
tion and reporter activity (Fig. 3A and B). We found that SMAD1/
5/8 is also phosphorylated via TGF-b and ALK-5 in some glioma
cell lines andmay contribute to enhanced VEGF release (Fig. 3A,
Fig. 4A and D). Sufficient TGF-bRII cell surface expression and
phosphorylation of SMAD2/3 are necessary, but not sufficient,
for SBE activation (Fig. 3B) and VEGF release (Fig. 3C), suggest-
ing the involvement of additional downstream effectors. That
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Fig. 4. TGF-b–dependent increase of VEGF is mediated by ALK-5 and involves different SMAD signaling pathways. (A) U87MG or ZH-161 cells were
treated with or without SD-208 (1 mM, 25 h) or (siRNA) targeting ALK-5 (72 h for U87MG, 48 h for ZH161) and 24 hours before harvesting with or
without TGF-b2 (10 ng/mL). Total SMAD2, pSMAD2, SMAD3, pSMAD3, SMAD5, pSMAD1/5/8, or GAPDH were analyzed by immunoblot. Supernatants
were analyzed for VEGF by ELISA. (B) Levels of total SMAD2, pSMAD2, SMAD3, pSMAD3, SMAD5, pSMAD1/5/8, or GAPDH were assessed by
immunoblot after silencing of SMAD2 (24 h), SMAD3 (36 h for U87MG, 24 h for ZH-161), SMAD2 and SMAD3 (ZH-161, 24 h) or SMAD5 (24 h)
with or without additional treatment with TGF-b2 (10 ng/mL, 12–24 h). (C) Effect of silencing of SMAD2, SMAD3, or SMAD5, or respective
controls on transcriptional activation in U87MG or ZH-161 cells with or without treatment with TGF-b2 (10 ng/mL, 12 h) was examined by SBE
reporter assay. Shown are relative units of SBE reporter signal normalized to untreated control-transfected samples. (D) Supernatants from
cells treated as in B were assessed for VEGF by ELISA.
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high constitutive levels of pSMAD2 negatively correlated with
the inducibility of pSMAD2 by exogenous TGF-b suggests a sat-
uration of the signaling pathway by autocrine TGF-b that leads
to decreased sensitivity towards exogenous TGF-b. ALK-5 ex-
pression was not predictive for sensitivity to exogenous TGF-b
because cell lines with poor activation of the SBE reporter ex-
pressed rather high levels of ALK-5 and vice versa. Posttran-
scriptional processes (eg, involving deubiquitinating enzymes
regulating TGF-b receptor stability39) probably modulate sensi-
tivity towards TGF-b.
Exogenous TGF-b induced VEGF release in most cell lines
(Fig. 3C). Cells unresponsive to TGF-b were still responsive to
hypoxia with regard to VEGF induction, placing differential reg-
ulation upstream of the VEGF promoter (Fig. 3D). TGF-b–depen-
dent SMAD3 phosphorylation and transcriptional SBE activation
correlated with TGF-b–evoked VEGF release, although no such
correlation was seen for pSMAD2 or the TGF-b target gene,
PAI-1. A differential activation of the transcription factor Sp1,
a major driver of VEGF gene expression in nonhypoxic condi-
tions40 via competing SMAD signaling pathways, might play a
role in this context. Of note, the VEGF promoter itself contains
SBE sites, and promoter activity is increased by SMADs.41 That
depletion of SMAD5 led to increased constitutive VEGF release
(Fig. 2H), but reduced TGF-b evoked VEGF release (Fig. 4D) in
U87MG cells might be best explained via the dual activation
of pSMAD1/5/8 by TGF-b and BMP. While endogenous BMP sig-
naling might inhibit constitutive VEGF expression, either indi-
rectly via destabilization of HIF37 or directly via BMP-9-ALK1
signaling as described for endothelial cells,38 a relative predom-
inance of TGF-b signaling might occur in the pharmacological
context of exogenous stimulation by TGF-b inducing VEGF
both via pSMAD2/3 and pSMAD1/5/8 signaling (Fig. 5).
In summary, we show that TGF-b regulation of VEGF release
in glioma cells depends, in an ALK-5–dependent manner, not
only on SMAD2/3-dependent pathways but also on pSMAD1/
5/8 signaling, suggesting that anti-TGF-b strategies may indi-
rectly inhibit VEGF pathway activation in glioblastoma and
that this mechanism accounts for some of the angiogenic ac-
tivity attributed to TGF-b. Moreover, since we have recently il-
lustrated how integrin inhibition downregulates TGF-b
pathway activation in glioblastoma,42 combinatorial therapeu-
tic approaches targeting sequentially or parallel integrins TGF-b
and VEGF based on preferential pathway activation may allow
better treatment options for glioblastoma.
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